Janssen Seeking European Approval for Carvykti as Earlier Refractory Multiple Myeloma Treatment
The firm submitted data from CARTITUDE-4, which showed the CAR T-cell therapy improved patients' progression-free survival compared to standard-of-care regimens.
Nexcella CAR T-Cell Therapy Amyloidosis Trial Yields Promising Safety, Efficacy Data
At ASGCT's annual meeting, researchers shared data suggesting that the autologous cell therapy could benefit patients with the rare, multiple myeloma-associated disease.
In presentations at AACR, researchers discussed how drug sensitivity and other functional testing is improving precision oncology amid systemic barriers.
BMS, 2seventy's Supplemental Abecma Submissions Being Reviewed by Regulators in US, Europe, Japan
The companies have submitted data from the KarMMa-3 trial hoping to advance the CAR T-cell therapy as an earlier treatment for refractory multiple myeloma patients.
K36 Therapeutics Treats First Multiple Myeloma Patient in Phase I Trial of KTX-1001
The firm is evaluating its investigational MMSET inhibitor in patients with relapsed or refractory multiple myeloma harboring t(4;14) genetic translocations.